| Name | Title | Contact Details |
|---|
Notal Vision was founded in 2000 by ophthalmologists and medical device professionals determined to reduce vision loss associated with age-related macular degeration (AMD). With leading experts in the field, this team of medical professionals and scientists developed a new, patented technology for monitoring AMD. This new technology, Preferential Hyperacuity Perimetry, is now providing eye care professionals around the world with valuable clinical data for monitoring patients with AMD.
Cyto Pulse Sciences is a Glen Burnie, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Smh Radiology Associates Corporate Office is a Sarasota, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Medical Imaging Northwest is a Lakewood, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within the human tumor microenvironment to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce is developing two clinical-stage programs as well as advancing and building out its broad and wholly-owned discovery pipeline of immuno-oncology targets, including those expressed on T-regulatory cells, macrophages and stromal cells. Jounce`s lead product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS and is currently being assessed in a Phase 2 clinical trial. JTX-4014 is a PD-1 inhibitor intended for use in combination with future pipeline products, and Jounce has completed enrollment in the JTX-4014 Phase 1 clinical trial. In addition, Jounce has exclusively licensed worldwide rights to JTX-8064, a LILRB2 receptor antagonist, to Celgene. For more information, please visit www.jouncetx.com. We have many career opportunities at Jounce and are looking for exceptional individuals who share our passion and perseverance for developing highly durable cancer immunotherapies that can dramatically impact and improve patients` lives.